|
BlossomHill Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
12% |
|
|
3,615,362 |
|
Chen Bihua |
06 Aug 2026 |
| CUE |
Cue Biopharma, Inc. |
Common Stock, par value $0.001 per share |
10% |
$15,487,248 |
|
791,377 |
|
Cormorant Asset Management, LP |
30 Sep 2026 |
| IBIO |
iBio, Inc. |
Common Stock, $0.001 par value per share |
10% |
$7,420,347 |
+$4,160,733 |
5,117,481 |
+128% |
Cormorant Asset Management, LP |
30 Jun 2026 |
| QNCX |
Quince Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
10% |
$1,863,500 |
|
108,029 |
|
Cormorant Asset Management, LP |
30 Jun 2026 |
| IBIO |
iBio, Inc. |
Common Stock, $0.001 par value per share |
10% |
|
|
3,834,335 |
|
Cormorant Asset Management, LP |
31 Mar 2026 |
| DRUG |
Bright Minds Biosciences Inc. |
Common Shares |
8.1% |
$41,088,000 |
-$5,136,000 |
800,000 |
-11% |
Cormorant Asset Management, LP |
30 Sep 2026 |
| CRBP |
Corbus Pharmaceuticals Holdings, Inc. |
Common Stock, par value $0.0001 per share |
7.8% |
$8,235,000 |
-$4,638,891 |
1,500,000 |
-36% |
Cormorant Asset Management, LP |
31 Oct 2026 |
| RLYB |
Rallybio Corp |
Common Stock, par value $0.0001 per share |
7.6% |
$232,000 |
|
400,000 |
|
Cormorant Asset Management, LP |
31 Mar 2026 |
| CRGX |
CARGO Therapeutics, Inc. |
Common stock, par value $0.001 per share |
7.3% |
$15,655,313 |
|
3,381,277 |
|
Cormorant Asset Management, LP |
31 Mar 2025 |
| ANL |
Adlai Nortye Ltd. |
American Depositary Shares, each representing three Class A Ordinary Shares |
6.8% |
$36,758,836 |
+$9,982,637 |
3,978,229 |
+37% |
Cormorant Asset Management, LP |
30 Jun 2026 |
| EYPT |
EyePoint, Inc. |
Common Stock, par value $0.001 |
6.7% |
$17,652,500 |
-$3,837,500 |
5,750,000 |
-18% |
Cormorant Asset Management, LP |
30 Sep 2026 |
| IRD |
Opus Genetics, Inc. |
Common Stock, par value $0.0001 per share |
6.6% |
$23,320,000 |
|
5,500,000 |
|
Cormorant Asset Management, LP |
30 Sep 2026 |
| ETRA |
Electra Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
5.4% |
$28,977,239 |
|
3,365,533 |
|
Cormorant Asset Management, LP |
30 Sep 2026 |
| RAPP |
Rapport Therapeutics, Inc. |
Common Stock, $0.001 par value per share |
5.1% |
$82,572,706 |
-$6,720,000 |
2,457,521 |
-7.5% |
Cormorant Asset Management, LP |
30 Sep 2026 |
| AGMB |
Agomab Therapeutics NV |
American Depositary Shares, each representing one common share, no nominal value per share |
5% |
$25,171,203 |
|
2,465,348 |
|
Cormorant Asset Management, LP |
31 Mar 2026 |
| BIOA |
BioAge Labs, Inc. |
Common Stock, par value $0.00001 per share |
4.9% |
$13,309,194 |
-$891,000 |
2,240,605 |
-6.3% |
Cormorant Asset Management, LP |
30 Sep 2026 |
| MLTX |
MoonLake Immunotherapeutics |
Class A ordinary share, par value $0.0001 per share |
4.4% |
$65,262,616 |
-$25,959,000 |
3,205,433 |
-28% |
Cormorant Asset Management, LP |
30 Jun 2026 |
| PRAX |
Praxis Precision Medicines, Inc. |
Common Stock, par value $0.0001 per share |
4% |
$53,000,000 |
-$33,125,000 |
1,000,000 |
-38% |
Cormorant Asset Management, LP |
30 Sep 2025 |
| CABA |
Cabaletta Bio, Inc. |
Common Stock, par value $0.00001 per share |
2.6% |
$8,865,000 |
-$10,835,000 |
4,500,000 |
-55% |
Cormorant Asset Management, LP |
30 Sep 2026 |
| BMEA |
Biomea Fusion, Inc. |
Common Stock |
1.5% |
$2,143,436 |
-$5,295,734 |
1,060,792 |
-71% |
Chen Bihua |
22 Oct 2025 |
| OKUR |
OnKure Therapeutics, Inc. |
Class A Common Stock, par value $0.0001 per share |
0% |
$0 |
|
0 |
|
Cormorant Asset Management, LP |
15 May 2025 |
| VYNE |
VYNE Therapeutics Inc. |
Common Stock, par value $0.0001 per share |
0% |
$0 |
-$459,264 |
0 |
-100% |
Cormorant Asset Management, LP |
30 Sep 2025 |
| ENGN |
enGene Holdings Inc. |
Common Shares |
0% |
$0 |
-$27,040,000 |
0 |
-100% |
Cormorant Asset Management, LP |
31 Mar 2026 |
| KALA |
KALA BIO, Inc. |
Common Stock, $0.001 par value per share |
0% |
$0 |
-$931,568 |
0 |
-100% |
Cormorant Asset Management, LP |
30 Sep 2025 |
| RLYB |
Rallybio Corp |
Common Stock, par value $0.0001 per share |
0% |
$0 |
|
0 |
|
Cormorant Asset Management, LP |
30 Jun 2026 |